Insulin resistance

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Insulin resistance
Specialty Endocrinology

Insulin resistance (IR) is a pathological condition in which cells fail to respond normally to the hormone insulin. The body produces insulin when glucose starts to be released into the bloodstream from the digestion of carbohydrates (primarily) in the diet. Under normal conditions of insulin reactivity, this insulin response triggers glucose being taken into body cells, to be used for energy, and inhibits the body from using fat for energy, thereby causing the concentration of glucose in the blood to decrease as a result, staying within the normal range even when a large amount of carbohydrates is consumed. During insulin resistance, however, excess glucose is not sufficiently absorbed by cells even in the presence of insulin, thereby causing an increase in the level of blood sugar.

Overview[edit]

When the body produces insulin under conditions of insulin resistance, the cells are resistant to the insulin and are unable to use it as effectively, leading to high blood sugar. Beta cells in the pancreas subsequently increase their production of insulin, further contributing to a high blood insulin level. This often remains undetected and can contribute to the development of type 2 diabetes or latent autoimmune diabetes of adults.[1] Although this type of chronic insulin resistance is harmful, during acute illness it is actually a well-evolved protective mechanism.

Recent investigations have revealed that insulin resistance helps to conserve the brain's glucose supply by preventing muscles from taking up excessive glucose;[2] in theory, insulin resistance should even be strengthened under harsh metabolic conditions such as pregnancy, during which the expanding fetal brain demands more glucose.

People who develop type 2 diabetes usually pass through earlier stages of insulin resistance and prediabetes, although those often go undiagnosed. Insulin resistance is a syndrome (a set of signs and symptoms) resulting from reduced insulin activity; it is also part of a larger constellation of symptoms called the metabolic syndrome.

Insulin resistance may also develop in patients who have recently experienced abdominal or bariatric procedures,[3] this acute form of insulin resistance that may result post-operatively tends to increase over the short term, with sensitivity to insulin typically returning to patients after about five days.[4]

Signs and symptoms[edit]

These depend on poorly understood variations in individual biology and consequently may not be found with all people diagnosed with insulin resistance.[5]

  • Increased hunger
  • Lethargy (tiredness)
  • Brain fogginess and inability to focus
  • High blood sugar
  • Weight gain, fat storage, difficulty losing weight – for most people, excess weight is from high subcutaneous fat storage; the fat in IR is generally stored in and around abdominal organs in both males and females; it is currently suspected that hormones produced in that fat are a precipitating cause of insulin resistance
  • Increased blood cholesterol levels
  • Increased blood pressure; many people with hypertension are either diabetic or pre-diabetic and have elevated insulin levels due to insulin resistance; one of insulin's effects is to control arterial wall tension throughout the body
  • Acanthosis nigricans – insulin prevents lipolysis of adipose tissues. In the setting of insulin resistance, there is elevated lipolysis and release of free fatty acids into the blood stream which contributes to further insulin resistance via increasing hepatic gluconeogenesis and preventing insulin dependent glucose uptake in tissues.

Associated risk factors[edit]

Several associated risk factors include the following:

Cause[edit]

Molecular mechanism[edit]

Insulin resistance implies that the body's cells (primarily muscle) lose sensitivity to insulin, a hormone secreted by the pancreas to promote glucose utilization, at the molecular level, a cell senses insulin through insulin receptors, with the signal propagating through a cascade of molecules collectively known as PI3K/Akt/mTOR signaling pathway.[12] Recent studies suggested that the pathway may operate as a bistable switch under physiologic conditions for certain types of cells, and insulin response may well be a threshold phenomenon.[2][12][13] The pathway's sensitivity to insulin may be blunted by many factors such as free fatty acids,[14] causing insulin resistance, from a broader perspective, however, sensitivity tuning (including sensitivity reduction) is a common practice for an organism to adapt to the changing environment or metabolic conditions.[15] Pregnancy, for example, is a prominent change of metabolic conditions, under which the mother has to reduce her muscles' insulin sensitivity to spare more glucose for the brains (the mother's brain and the fetal brain), this can be achieved through raising the response threshold (i.e., postponing the onset of sensitivity) by secreting placental growth factor to interfere with the interaction between insulin receptor substrate (IRS) and PI3K, which is the essence of the so-called adjustable threshold hypothesis of insulin resistance.[2]

Diet[edit]

It is well known that insulin regulates the conversion of carbohydrates into fats (triglycerides) by promoting the absorption of, especially, glucose from the blood into fat cells.[16] The intake of simple sugars, and particularly fructose, is a factor that contributes to insulin resistance.[17][18] Fructose is metabolized by the liver into triglycerides, and, as mentioned above, tends to raise their levels in the blood stream. High levels of fructose or sucrose (table sugar) induce insulin resistance in rats,[19][20] and this insulin resistance is alleviated by fish oil supplementation.[21]

Once established, insulin resistance would result in increased circulating levels of insulin, since insulin is the primary hormonal signal for energy storage into fat cells, which tend to retain their sensitivity in the face of hepatic and skeletal muscle resistance, IR stimulates the formation of new fatty tissue and accelerates weight gain.[22]

Insulin resistance and type 2 diabetes are associated with excess body weight.[23][24] A possible explanation is that both insulin resistance and obesity often have the same cause, systematic overeating, which has the potential to lead to insulin resistance and obesity due to repeated administration of excess levels of glucose, which stimulate insulin secretion; excess levels of fructose, which raise triglyceride levels in the bloodstream; and fats, which may be absorbed easily by the adipose cells, and tend to end up as fatty tissue in a hypercaloric diet.[citation needed] Some scholars go as far as to claim that neither insulin resistance, nor obesity really are metabolic disorders per se, but simply adaptive responses to sustained caloric surplus, intended to protect bodily organs from lipotoxicity (unsafe levels of lipids in the bloodstream and tissues): "Obesity should therefore not be regarded as a pathology or disease, but rather as the normal, physiologic response to sustained caloric surplus... As a consequence of the high level of lipid accumulation in insulin target tissues including skeletal muscle and liver, it has been suggested that exclusion of glucose from lipid-laden cells is a compensatory defense against further accumulation of lipogenic substrate."[25]

Fast food meals combined with drinks containing sugar typically possess several characteristics, all of which have independently been linked to IR: they are sugar rich, palatable, and cheap, increasing risk of overeating and leptin resistance; simultaneously, they are high in dietary fat and fructose, and low in omega-3 and fiber; and they usually have high glycemic indices.[22] Overconsumption of cheap sugar rich meals and beverages have been proposed as a fundamental factor behind the metabolic syndrome epidemic and all its constituents.

An American study has shown that glucosamine (often prescribed for joint problems) may cause insulin resistance.[26] Other studies, however, could not confirm a significant effect on blood glucose or insulin resistance.[27][28][29]

Vitamin D deficiency also is associated with insulin resistance.[30]

Elevated levels of free fatty acids and triglycerides in the blood stream and tissues also have been found in many studies to occur in states of insulin resistance.[31][32][33][34] Triglyceride levels are driven by a variety of dietary factors.

In studies on animals caloric intake that is far in excess of animals' energy needs results in rapid weight gain and significant insulin resistance after just three weeks (in rats).[35][31]

Sedentary lifestyle[edit]

Sedentary lifestyle increases the likelihood of development of insulin resistance,[36][37] it has been estimated that each 500 kcal/week increment in physical activity related energy expenditure, reduces the lifetime risk of type 2 diabetes by 9%.[38] A different study found that vigorous exercise at least once a week reduced the risk of type 2 diabetes in women by 33%.[39]

Protease inhibitors[edit]

Protease inhibitors found in HIV drugs are linked to insulin resistance.[40]

Cellular level[edit]

At the cellular level, much of the variance in insulin sensitivity between untrained, non-diabetic humans may be explained by two mechanisms: differences in phospholipid profiles of skeletal muscle cell membranes, and in intramyocellular lipid (ICML) stores within these cells.[41] High levels of lipids in the bloodstream have the potential to result in accumulation of triglycerides and their derivatives within muscle cells, which activate proteins Kinase C-ε and C-θ, ultimately reducing the glucose uptake at any given level of insulin,[32][42] this mechanism is quite fast-acting and may induce insulin resistance within days or even hours in response to a large lipid influx.[43] Draining the intracellular reserves, on the other hand, is more challenging: moderate caloric restriction alone, even over a period of several months, appears to be ineffective,[44][45] and it must be combined with physical exercise to have any effect.

In the long term, diet has the potential to change the ratio of polyunsaturated to saturated phospholipids in cell membranes, correspondingly changing cell membrane fluidity; full impact of such changes is not fully understood, but it is known that the percentage of polyunsaturated phospholipids is strongly inversely correlated with insulin resistance.[46] It is hypothesized that increasing cell membrane fluidity by increasing PUFA concentration might result in an enhanced number of insulin receptors, an increased affinity of insulin to its receptors, and a reduced insulin resistance, and vice versa.[47]

Many stressing factors may lead to increased cortisol in the bloodstream. Cortisol counteracts insulin, contributes to hyperglycemia-causing hepatic gluconeogenesis,[48] and inhibits the peripheral utilization of glucose, which eventually leads to insulin resistance.[48] It does this by decreasing the translocation of glucose transporters (especially GLUT4) to the cell membrane.[49][50]

Inflammation by itself also seems to be implicated in causing insulin resistance. Mice without JNK1-signaling do not develop insulin resistance under dietary conditions that normally produce it.[51][52] Recent study have found out the specific role of the MLK family of protein in the activation of JNK during obesity and insulin resistance.[53]

Rare type 2 diabetes cases sometimes use high levels of exogenous insulin, as short-term overdosing of insulin causes short-term insulin resistance, it has been hypothesized that chronic high dosing contributes to more permanent insulin resistance.[citation needed]

Molecular[edit]

At a molecular level, insulin resistance has been proposed to be a reaction to excess nutrition by superoxide dismutase in cell mitochondria that acts as an antioxidant defense mechanism, this link seems to exist under diverse causes of insulin resistance. It also is based on the finding that insulin resistance may be reversed rapidly by exposing cells to mitochondrial uncouplers, electron transport chain inhibitors, or mitochondrial superoxide dismutase mimetics.[54]

Disease[edit]

Recent research and experimentation has uncovered a non-obesity related connection to insulin resistance and type 2 diabetes, it has long been observed that patients who have had some kinds of bariatric surgery have increased insulin sensitivity and even remission of type 2 diabetes. It was discovered that diabetic/insulin resistant non-obese rats whose duodenum has been removed surgically, also experienced increased insulin sensitivity[55] and remission of type 2 diabetes, this suggested similar surgery in humans, and early reports in prominent medical journals[56] are that the same effect is seen in humans, at least the small number who have participated in the experimental surgical program. The speculation is, that some substance is produced in the mucosa of that initial portion of the small intestine that signals body cells to become insulin resistant. If the producing tissue is removed, the signal ceases and body cells revert to normal insulin sensitivity. No such substance has been found as yet, and the existence of such a substance remains speculative.[citation needed]

Insulin resistance is associated with PCOS.[57]

HCV and insulin resistance[edit]

Hepatitis C also makes people three to four times more likely to develop type 2 diabetes and insulin resistance;[10] in addition, "people with Hepatitis C who develop diabetes probably have susceptible insulin-producing cells, and probably would get it anyway, but much later in life.[10] The extra insulin resistance caused by Hepatitis C apparently brings on diabetes at age 35 or 40, instead of 65 or 70."[10]

Pathophysiology[edit]

One of insulin's functions is to regulate delivery of glucose into cells to provide them with energy.[58] Insulin resistant cells cannot take in glucose, amino acids and fatty acids. Thus, glucose, fatty acids and amino acids 'leak' out of the cells. A decrease in insulin/glucagon ratio inhibits glycolysis which in turn decreases energy production, the resulting increase in blood glucose may raise levels outside the normal range and cause adverse health effects, depending on dietary conditions.[59] Certain cell types such as fat and muscle cells require insulin to absorb glucose. When these cells fail to respond adequately to circulating insulin, blood glucose levels rise, the liver helps regulate glucose levels by reducing its secretion of glucose in the presence of insulin. This normal reduction in the liver's glucose production may not occur in people with insulin resistance.[60]

Insulin resistance in muscle and fat cells reduces glucose uptake (and also local storage of glucose as glycogen and triglycerides, respectively), whereas insulin resistance in liver cells results in reduced glycogen synthesis and storage and also a failure to suppress glucose production and release into the blood. Insulin resistance normally refers to reduced glucose-lowering effects of insulin. However, other functions of insulin can also be affected, for example, insulin resistance in fat cells reduces the normal effects of insulin on lipids and results in reduced uptake of circulating lipids and increased hydrolysis of stored triglycerides. Increased mobilization of stored lipids in these cells elevates free fatty acids in the blood plasma. Elevated blood fatty-acid concentrations (associated with insulin resistance and diabetes mellitus Type 2), reduced muscle glucose uptake, and increased liver glucose production all contribute to elevated blood glucose levels. High plasma levels of insulin and glucose due to insulin resistance are a major component of the metabolic syndrome. If insulin resistance exists, more insulin needs to be secreted by the pancreas. If this compensatory increase does not occur, blood glucose concentrations increase and type 2 diabetes or latent autoimmune diabetes of adults occurs.[59][61]

Any food or drink containing glucose (or the digestible carbohydrates that contain it, such as sucrose, starch, etc.) causes blood glucose levels to increase. In normal metabolism, the elevated blood glucose level instructs beta (β) cells in the Islets of Langerhans, located in the pancreas, to release insulin into the blood, the insulin, in turn, makes insulin-sensitive tissues in the body (primarily skeletal muscle cells, adipose tissue, and liver) absorb glucose, and thereby lower the blood glucose level. The beta cells reduce insulin output as the blood glucose level falls, allowing blood glucose to settle at a constant of approximately 5 mmol/L (mM) (90 mg/dL). In an insulin-resistant person, normal levels of insulin do not have the same effect in controlling blood glucose levels, during the compensated phase on insulin resistance, insulin levels are higher, and blood glucose levels are still maintained. If compensatory insulin secretion fails, then either fasting (impaired fasting glucose) or postprandial (impaired glucose tolerance) glucose concentrations increase. Eventually, type 2 diabetes or latent autoimmune diabetes occurs when glucose levels become higher throughout the day as the resistance increases and compensatory insulin secretion fails, the elevated insulin levels also have additional effects (see insulin) that cause further abnormal biological effects throughout the body.[citation needed]

The most common type of insulin resistance is associated with overweight and obesity in a condition known as the metabolic syndrome. Insulin resistance often progresses to full Type 2 diabetes mellitus (T2DM) or latent autoimmune diabetes of adults.[62][63] This often is seen when hyperglycemia develops after a meal, when pancreatic β-cells are unable to produce sufficient insulin to maintain normal blood sugar levels (euglycemia) in the face of insulin resistance, the inability of the β-cells to produce sufficient insulin in a condition of hyperglycemia is what characterizes the transition from insulin resistance to T2DM.[64]

Various disease states make body tissues more resistant to the actions of insulin. Examples include infection (mediated by the cytokine TNFα) and acidosis. Recent research is investigating the roles of adipokines (the cytokines produced by adipose tissue) in insulin resistance. Certain drugs also may be associated with insulin resistance (e.g., glucocorticoids).[citation needed]

The presence of insulin leads to a kind of insulin resistance; every time a cell is exposed to insulin, the production of GLUT4 (Glucose transporter type 4) on the membrane of the cell decreases somewhat.[65] In the presence of a higher than usual level of insulin (generally caused by insulin resistance), this down-regulation acts as a kind of positive feedback, increasing the need for insulin. Exercise reverses this process in muscle tissue,[66] but if it is left unchecked, it may contribute to insulin resistance.

Elevated blood levels of glucose—regardless of cause—lead to increased glycation of proteins with changes, only a few of which are understood in any detail, in protein function throughout the body.[67][68]

Insulin resistance often is found in people with visceral adiposity (i.e., a high degree of fatty tissue within the abdomen—as distinct from subcutaneous adiposity or fat between the skin and the muscle wall, especially elsewhere on the body, such as hips or thighs), hypertension, hyperglycemia, and dyslipidemia involving elevated triglycerides, small dense low-density lipoprotein (sdLDL) particles, and decreased HDL cholesterol levels. With respect to visceral adiposity, a great deal of evidence suggests two strong links with insulin resistance. First, unlike subcutaneous adipose tissue, visceral adipose cells produce significant amounts of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-a), and Interleukins-1 and −6, etc. In numerous experimental models, these proinflammatory cytokines disrupt normal insulin action in fat and muscle cells, and may be a major factor in causing the whole-body insulin resistance observed in patients with visceral adiposity. Much of the attention on production of proinflammatory cytokines has focused on the IKK-beta/NF-kappa-B pathway, a protein network that enhances transcription of inflammatory markers and mediators that may cause insulin resistance. Second, visceral adiposity is related to an accumulation of fat in the liver, a condition known as non-alcoholic fatty liver disease (NAFLD). The result of NAFLD is an excessive release of free fatty acids into the bloodstream (due to increased lipolysis), and an increase in hepatic glycogenolysis and hepatic glucose production, both of which have the effect of exacerbating peripheral insulin resistance and increasing the likelihood of Type 2 diabetes mellitus.[citation needed]

Also, insulin resistance often is associated with a hypercoagulable state (impaired fibrinolysis) and increased inflammatory cytokine levels.[69]

Diagnosis[edit]

Fasting insulin levels[edit]

A fasting serum insulin level greater than 25 mIU/L or 174 pmol/L is considered insulin resistance, the same levels apply three hours after the last meal.[70]

Glucose tolerance testing[edit]

During a glucose tolerance test (GTT), which may be used to diagnose diabetes mellitus, a fasting patient takes a 75 gram oral dose of glucose. Then blood glucose levels are measured over the following two hours.

Interpretation is based on WHO guidelines, after two hours a glycemia less than 7.8 mmol/L (140 mg/dL) is considered normal, a glycemia of between 7.8 and 11.0 mmol/L (140 to 197 mg/dL) is considered as impaired glucose tolerance (IGT), and a glycemia of greater than or equal to 11.1 mmol/L (200 mg/dL) is considered diabetes mellitus.

An oral glucose tolerance test (OGTT) may be normal or mildly abnormal in simple insulin resistance. Often, there are raised glucose levels in the early measurements, reflecting the loss of a postprandial peak (after the meal) in insulin production. Extension of the testing (for several more hours) may reveal a hypoglycemic "dip," that is a result of an overshoot in insulin production after the failure of the physiologic postprandial insulin response.[citation needed]

Measuring insulin resistance[edit]

Hyperinsulinemic euglycemic clamp[edit]

The gold standard for investigating and quantifying insulin resistance is the "hyperinsulinemic euglycemic clamp," so-called because it measures the amount of glucose necessary to compensate for an increased insulin level without causing hypoglycemia.[71] It is a type of glucose clamp technique, the test rarely is performed in clinical care, but is used in medical research, for example, to assess the effects of different medications. The rate of glucose infusion commonly is referred to in diabetes literature as the GINF value.[72]

The procedure takes about two hours. Through a peripheral vein, insulin is infused at 10–120 mU per m2 per minute. In order to compensate for the insulin infusion, glucose 20% is infused to maintain blood sugar levels between 5 and 5.5 mmol/L. The rate of glucose infusion is determined by checking the blood sugar levels every five to ten minutes.[72]

The rate of glucose infusion during the last thirty minutes of the test determines insulin sensitivity. If high levels (7.5 mg/min or higher) are required, the patient is insulin-sensitive. Very low levels (4.0 mg/min or lower) indicate that the body is resistant to insulin action. Levels between 4.0 and 7.5 mg/min are not definitive, and suggest "impaired glucose tolerance," an early sign of insulin resistance.[72]

This basic technique may be enhanced significantly by the use of glucose tracers. Glucose may be labeled with either stable or radioactive atoms. Commonly used tracers are 3-3H glucose (radioactive), 6,6 2H-glucose (stable) and 1-13C Glucose (stable). Prior to beginning the hyperinsulinemic period, a 3h tracer infusion enables one to determine the basal rate of glucose production, during the clamp, the plasma tracer concentrations enable the calculation of whole-body insulin-stimulated glucose metabolism, as well as the production of glucose by the body (i.e., endogenous glucose production).[72]

Modified insulin suppression test[edit]

Another measure of insulin resistance is the modified insulin suppression test developed by Gerald Reaven at Stanford University, the test correlates well with the euglycemic clamp, with less operator-dependent error. This test has been used to advance the large body of research relating to the metabolic syndrome.[72]

Patients initially receive 25 μg of octreotide (Sandostatin) in 5 mL of normal saline over 3 to 5 minutes via intravenous infusion (IV) as an initial bolus, and then, are infused continuously with an intravenous infusion of somatostatin (0.27 μg/m2/min) to suppress endogenous insulin and glucose secretion. Next, insulin and 20% glucose are infused at rates of 32 and 267 mg/m2/min, respectively. Blood glucose is checked at zero, 30, 60, 90, and 120 minutes, and thereafter, every 10 minutes for the last half-hour of the test, these last four values are averaged to determine the steady-state plasma glucose level (SSPG). Subjects with an SSPG greater than 150 mg/dL are considered to be insulin-resistant.[72]

Alternatives[edit]

Given the complicated nature of the "clamp" technique (and the potential dangers of hypoglycemia in some patients), alternatives have been sought to simplify the measurement of insulin resistance, the first was the Homeostatic Model Assessment (HOMA), and a more recent method is the Quantitative insulin sensitivity check index (QUICKI). Both employ fasting insulin and glucose levels to calculate insulin resistance, and both correlate reasonably with the results of clamping studies. Wallace et al. point out that QUICKI is the logarithm of the value from one of the HOMA equations.[73]

Management[edit]

The primary treatment for insulin resistance is exercise and weight loss. Research shows that a low-carbohydrate diet may help.[74] Both metformin and thiazolidinediones improve insulin resistance, but only are approved therapies for type 2 diabetes, not for insulin resistance. By contrast, growth hormone replacement therapy may be associated with increased insulin resistance.[75]

Metformin has become one of the more commonly prescribed medications for insulin resistance.[76] Unfortunately, Metformin also masks Vitamin B12 deficiency, so accompanying sub-lingual Vitamin B12 tablets are recommended.

Insulin resistance is often associated with abnormalities in lipids particularly high blood triglycerides and low high density lipoprotein.[31][32]

The Diabetes Prevention Program (DPP) showed that exercise and diet were nearly twice as effective as metformin at reducing the risk of progressing to type 2 diabetes.[77] However, the participants in the DPP trial regained about 40% of the weight that they had lost at the end of 2.8 years, resulting in a similar incidence of diabetes development in both the lifestyle intervention and the control arms of the trial.[78] One 2009 study found that carbohydrate deficit after exercise, but not energy deficit, contributed to insulin sensitivity increase.[79]

Resistant starch from high-amylose corn, amylomaize, has been shown to reduce insulin resistance in healthy individuals, in individuals with insulin resistance, and in individuals with type 2 diabetes.[80] Animal studies demonstrate that it cannot reverse damage already done by high glucose levels, but that it reduces insulin resistance and reduces the development of further damage.[81][82][83]

Some types of polyunsaturated fatty acids (omega-3) may moderate the progression of insulin resistance into type 2 diabetes,[84][85][86] however, omega-3 fatty acids appear to have limited ability to reverse insulin resistance, and they cease to be efficacious once type 2 diabetes is established.[87]

Caffeine intake limits insulin action, but not enough to increase blood-sugar levels in healthy persons. People who already have type 2 diabetes may see a small increase in levels if they take 2 or 2-1/2 cups of coffee per day.[88]

History[edit]

The concept that insulin resistance may be the underlying cause of diabetes mellitus type 2 was first advanced by Professor Wilhelm Falta and published in Vienna in 1931,[89] and confirmed as contributory by Sir Harold Percival Himsworth of the University College Hospital Medical Centre in London in 1936,[90] however, type 2 diabetes does not occur unless there is concurrent failure of compensatory insulin secretion.[91]

See also[edit]

References[edit]

  1. ^ Chiu HK, Tsai EC, Juneja R, et al. (August 2007). "Equivalent insulin resistance". Diabetes Research and Clinical Practice. 77 (2): 237–44. doi:10.1016/j.diabres.2006.12.013. PMID 17234296. 
  2. ^ a b c Wang, Guanyu (2014-12-06). "Raison d'être of insulin resistance: the adjustable threshold hypothesis". Journal of the Royal Society Interface. 11 (101): 20140892. doi:10.1098/rsif.2014.0892. ISSN 1742-5689. PMC 4223910 Freely accessible. PMID 25320065. 
  3. ^ "Insulin resistance: a marker of surgical stress : Current Opinion in Clinical Nutrition & Metabolic Care". LWW. 
  4. ^ Thorell, A.; Efendic, S.; Gutniak, M.; Häggmark, T.; Ljungqvist, O. (1994-01-01). "Insulin resistance after abdominal surgery". British Journal of Surgery. 81 (1): 59–63. doi:10.1002/bjs.1800810120. ISSN 1365-2168. PMID 8313123. 
  5. ^ Insulin resistance
  6. ^ Cao, H. (2000-01-01). "Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy". Human Molecular Genetics. 9 (1): 109–12. doi:10.1093/hmg/9.1.109. ISSN 0964-6906. PMID 10587585. 
  7. ^ Musso, Carla; Cochran, Elaine; Moran, Stephanie Ann; Skarulis, Monica C.; Oral, Elif Arioglu; Taylor, Simeon; Gorden, Phillip (July 2004). "Clinical Course of Genetic Diseases of the Insulin Receptor (Type A and Rabson-Mendenhall Syndromes): A 30-Year Prospective". Medicine. 83 (4): 209–22. doi:10.1097/01.md.0000133625.73570.54. ISSN 0025-7974. PMID 15232309. 
  8. ^ a b c d e f g h i j Mayfield, Jennifer (October 15, 1998). "Diagnosis and Classification of Diabetes Mellitus: New Criteria". American Academy of Family Physicians. Retrieved September 26, 2009. 
  9. ^ a b c d e f g h "Type 2 diabetes: Risk factors". Mayo Clinic. Retrieved 21 December 2011. 
  10. ^ a b c d Milner, KL; Van Der Poorten, D; Trenell, M; Jenkins, AB; Xu, A; Smythe, G; Dore, GJ; Zekry, A; et al. (2010). "Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance". Gastroenterology. 138 (3): 932–41.e3. doi:10.1053/j.gastro.2009.11.050. PMID 19962985. Lay summary – Science Daily (March 10, 2010). 
  11. ^ Yasuda, Keigo; Hines, III, Elbert; Kitabchi, Abbas E. (November 1982). "Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes". Journal of Clinical Endocrinology & Metabolism. 55 (5): 910–15. doi:10.1210/jcem-55-5-910. PMID 6749880. 
  12. ^ a b Wang, Guanyu (2010-01-01). "Singularity analysis of the AKT signaling pathway reveals connections between cancer and metabolic diseases". Physical Biology. 7 (4): 046015. Bibcode:2010PhBio...7d6015W. doi:10.1088/1478-3975/7/4/046015. ISSN 1478-3975. PMID 21178243. 
  13. ^ Wang, Guanyu (2012-10-07). "Optimal homeostasis necessitates bistable control". Journal of the Royal Society Interface. 9 (75): 2723–34. doi:10.1098/rsif.2012.0244. ISSN 1742-5689. PMC 3427521 Freely accessible. PMID 22535698. 
  14. ^ Lucidi, Paola; Rossetti, Paolo; Porcellati, Francesca; Pampanelli, Simone; Candeloro, Paola; Andreoli, Anna Marinelli; Perriello, Gabriele; Bolli, Geremia B.; Fanelli, Carmine G. (2010-06-01). "Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis". Diabetes. 59 (6): 1349–57. doi:10.2337/db09-0745. ISSN 1939-327X. PMC 2874695 Freely accessible. PMID 20299466. 
  15. ^ Wang Guanyu (Feb 5, 2016). "Tunable ultrasensitivity: functional decoupling and biological insights". Sci Rep. 6: 20345. Bibcode:2016NatSR...620345W. doi:10.1038/srep20345. PMC 4742884 Freely accessible. PMID 26847155. 
  16. ^ Stryer, Lubert (1995). Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. pp. 773–774. ISBN 0 7167 2009 4. 
  17. ^ Taubes, Gary (April 13, 2011). "Is sugar toxic?". The New York Times. 
  18. ^ Basciano, Heather; Federico, Lisa; Adeli, Khosrow (2005). "Fructose, insulin resistance, and metabolic dyslipidemia". Nutrition & Metabolism. 2 (1): 5. doi:10.1186/1743-7075-2-5. PMC 552336 Freely accessible. PMID 15723702. 
  19. ^ Thorburn, Anne W (1989). "Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats" (PDF). American Journal of Clinical Nutrition. 
  20. ^ Hwang, IS (1987). "Fructose-induced insulin resistance and hypertension in rats" (PDF). Hypertension. 10 (5): 512–16. doi:10.1161/01.HYP.10.5.512. 
  21. ^ Huang, YJ; Fang, VS; Juan, CC; Chou, YC; Kwok, CF; Ho, LT (November 1997). "Amelioration of insulin resistance and hypertension in a fructose-fed rat model with fish oil supplementation". Metab. Clin. Exp. 46 (11): 1252–58. doi:10.1016/S0026-0495(97)90226-2. PMID 9361681. 
  22. ^ a b Isganaitis, Elvira; Lustig, Robert H (2005). "Fast Food, Central Nervous System Insulin Resistance, and Obesity". Arteriosclerosis, Thrombosis, and Vascular Biology. 25 (12): 2451–62. doi:10.1161/01.ATV.0000186208.06964.91. PMID 16166564. 
  23. ^ "Obesity and elevated triglycerides". Med scape. 
  24. ^ http://www.nature.com/nature/journal/v444/n7121/full/nature05482.html
  25. ^ Unger, Roger H; Scherer, Philipp E (2010). "Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity" (PDF). Trends in Endocrinology & Metabolism. Archived from the original (PDF) on 2012-10-04. 
  26. ^ Pham, T; Cornea, A; Blick, KE; Jenkins, A; Scofield, RH (2007). "Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance". The American journal of the medical sciences. 333 (6): 333–39. doi:10.1097/MAJ.0b013e318065bdbe. PMID 17570985. 
  27. ^ Muniyappa R, Karne RJ, Hall G, et al. (November 2006). "Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects". Diabetes. 55 (11): 3142–50. doi:10.2337/db06-0714. PMID 17065354. 
  28. ^ Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits P, Tack CJ; Jacobs; Span; Lutterman; Smits; Tack (May 2001). "Short-term glucosamine infusion does not affect insulin sensitivity in humans". The Journal of Clinical Endocrinology and Metabolism. 86 (5): 2099–103. doi:10.1210/jc.86.5.2099. PMID 11344213. 
  29. ^ Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon TE; Blinn; Nuite; Silbert; McAlindon (February 2007). "Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis". Annals of the Rheumatic Diseases. 66 (2): 260–62. doi:10.1136/ard.2006.058222. PMC 1798503 Freely accessible. PMID 16818461. 
  30. ^ Chiu, KC; Chu, A; Go, VL; Saad, MF (2004). "Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction". The American Journal of Clinical Nutrition. 79 (5): 820–25. PMID 15113720. 
  31. ^ a b c Storlien, LH; Jenkins, AB; Chisholm, DJ; Pascoe, WS; Khouri, S; Kraegen, EW (1991). "Influence of dietary fat composition on development of insulin resistance in rats". Diabetes. 40 (2): 280–89. doi:10.2337/diabetes.40.2.280. PMID 1991575. 
  32. ^ a b c Schinner, S; Scherbaum, WA; Bornstein, SR; Barthel, A (2005). "Molecular mechanisms of insulin resistance". Diabetic Medicine. 22 (6): 674–82. doi:10.1111/j.1464-5491.2005.01566.x. PMID 15910615. 
  33. ^ Koyama, Kazunori; Chen, G; Lee, Y; Unger, RH (1997). "Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity". American Journal of Physiology. 273 (4 Pt 1): E708–13. PMID 9357799. 
  34. ^ Roden, Michael; Price, TB; Perseghin, G; Petersen, KF; Rothman, DL; Cline, GW; Shulman, GI (1996). "Mechanism of free fatty acid-induced insulin resistance in humans". Journal of Clinical Investigation. 97 (12): 2859–65. doi:10.1172/JCI118742. PMC 507380 Freely accessible. PMID 8675698. 
  35. ^ Kraegen, EW; Clark, PW; Jenkins, AB; Daley, EA; Chisholm, DJ; Storlien, LH (1991). "Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats". Diabetes. 40 (11): 1397–403. doi:10.2337/diabetes.40.11.1397. PMID 1936601. 
  36. ^ Ivy, JL (November 1997). "Role of exercise training in the prevention and treatment of insulin resistance and non-insulin-dependent diabetes mellitus". Sports Medicine. Auckland, NZ. 24 (5): 321–36. doi:10.2165/00007256-199724050-00004. PMID 9368278. 
  37. ^ Mayer-Davis, EJ; d'Agostino jr, R; Karter, AJ; Haffner, SM; Rewers, MJ; Saad, M; Bergman, RN (1998). "Intensity and amount of physical activity in relation to insulin sensitivity". JAMA: The Journal of the American Medical Association. 279 (9): 669–74. doi:10.1001/jama.279.9.669. PMID 9496984. 
  38. ^ Helmrich, Susan P; Ragland, David R; Leung, Rita W; Paffenbarger, Ralph S (1991). "Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus". New England Journal of Medicine. 325 (3): 147–52. doi:10.1056/NEJM199107183250302. PMID 2052059. 
  39. ^ Manson, JE; Rimm, EB; Stampfer, MJ; Willett, WC; Rosner, B; Hennekens, CH; Speizer, FE; Rimm, EB; Krolewski, AS (September 1991). "Physical activity and incidence of non-insulin-dependent diabetes mellitus in women". Lancet. 338 (8770): 774–78. doi:10.1016/0140-6736(91)90664-B. PMID 1681160. 
  40. ^ Fantry, Lori E (2003-03-24). "Protease Inhibitor-Associated Diabetes Mellitus: A Potential Cause of Morbidity and Mortality". JAIDS: Journal of Acquired Immune Deficiency Syndromes. Lippincott Williams & Wilkins. 32 (3){{inconsistent citations}} .
  41. ^ Haag, Marianne; Dippenaar, Nola G. (December 2005). "Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection" (PDF). Medical Science Monitor. 11 (12): RA359–67. PMID 16319806. Archived from the original (PDF) on 2011-10-08. 
  42. ^ Morino, K; Petersen, K; Shulman, G (2006). "Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction". Diabetes. 55 Suppl 2 (Suppl 2): S9–15. doi:10.2337/db06-S002. PMC 2995546 Freely accessible. PMID 17130651. 
  43. ^ Bachman, O; Dahl, DB; Brechtel, K; Machann, J; Haap, M; Maier, T; Loviscach, M; Stumvoll, M; et al. (2001). "Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans" (PDF). Diabetes. 50 (11): 2579–84. doi:10.2337/diabetes.50.11.2579. PMID 11679437. 
  44. ^ Sato, F; Tamura, Y; Watada, H; Kumashiro, N; Igarashi, Y; Uchino, H; Maehara, T; Kyogoku, S; et al. (2007). "Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects". The Journal of Clinical Endocrinology and Metabolism. 92 (8): 3326–29. doi:10.1210/jc.2006-2384. PMID 17519317. 
  45. ^ Tamura, Y; Tanaka, Y; Sato, F; Choi, JB; Watada, H; Niwa, M; Kinoshita, J; Ooka, A; et al. (2005). "Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients". The Journal of Clinical Endocrinology and Metabolism. 90 (6): 3191–96. doi:10.1210/jc.2004-1959. PMID 15769987. Archived from the original on 2012-07-16. 
  46. ^ Haugaard, SB; Madsbad, Sten; Hoy, Carl-Erik; Vaag, Allan (2006). "Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity". Clin Endocrinol. 64 (2): 169–78. doi:10.1111/j.1365-2265.2006.02444.x. PMID 16430716. 
  47. ^ Russo, Gian Luigi (2009). "Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention" (PDF). Biochemical Pharmacology. 77 (6): 937–46. doi:10.1016/j.bcp.2008.10.020. PMID 19022225. Archived from the original (PDF) on 2012-01-13. 
  48. ^ a b Brown, Dave D (2003). USMLE Step 1 Secrets. p. 63. 
  49. ^ King, Michael W (2005). Lange Q&A USMLE Step 1 (6th ed.). New York: McGraw-Hill Medical. p. 82. ISBN 0-07-144578-1. 
  50. ^ Piroli, GG; Grillo, CA; Reznikov, LR; Adams, S; McEwen, BS; Charron, MJ; Reagan, LP (2007). "Corticosterone Impairs Insulin-Stimulated Translocation of GLUT4 in the Rat Hippocampus". Neuroendocrinology. 85 (2): 71–80. doi:10.1159/000101694. PMID 17426391. 
  51. ^ Solinas, G; Vilcu, C; Neels, JG; Bandyopadhyay, GK; Luo, JL; Naugler, W; Grivennikov, S; Wynshaw-Boris, A; et al. (2007). "JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity". Cell Metabolism. 6 (5): 386–97. doi:10.1016/j.cmet.2007.09.011. PMID 17983584. 
  52. ^ "UCSD researchers discover inflammation, not obesity, cause of insulin resistance". D life. Archived from the original on 2007-11-21. Retrieved 2008-01-12. 
  53. ^ |Kant, S; Barrett, T; Vertii, A; Noh, YH; Jung, DY; Kim, JK; Davis, RJ (2013). "Role of the mixed-lineage protein kinase pathway in the metabolic stress response to obesity". Cell Rep. 4 (4): 681–88. doi:10.1016/j.celrep.2013.07.019. PMC 3769115 Freely accessible. PMID 23954791. 
  54. ^ Hoehn, KL; Salmon, AB; Hohnen-Behrens, C; Turner, N; Hoy, AJ; Maghzal, GJ; Stocker, R; Van Remmen, H; et al. (2009). "Insulin resistance is a cellular antioxidant defense mechanism". Proceedings of the National Academy of Sciences of the United States of America. 106 (42): 17787–92. Bibcode:2009PNAS..10617787H. doi:10.1073/pnas.0902380106. PMC 2764908 Freely accessible. PMID 19805130. 
  55. ^ Garrido-Sanchez, L. (2012). "Bypass of the duodenum improves insulin resistance much more rapidly than sleeve gastrectomy". Surgery or obesity and related diseases. 8 (2): 145–50. doi:10.1016/j.soard.2011.03.010. Retrieved 12 March 2017. 
  56. ^ Goodman, Alice (June 1, 2016). "Duodenal resurfacing achieves metabolic benefits in type 2 diabetes". Family Practice News. Retrieved 12 March 2017. 
  57. ^ Nafiye, Y; Sevtap, K; Muammer, D; Emre, O; Senol, K; Leyla, M (Apr 2010). "The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome". Fertility and Sterility. 93 (6): 1864–69. doi:10.1016/j.fertnstert.2008.12.024. PMID 19171332. 
  58. ^ "A heavy burden". The Economist. December 15, 2012. Retrieved 10 January 2013. 
  59. ^ a b "Insulin resistance". Medicine net. 
  60. ^ "Science daily". Jun 2009. 
  61. ^ Insulin Resistance Leads to LADA (Report). Diabetes Health. Retrieved Feb 21, 2015. 
  62. ^ Behme MT, Dupre J, Harris SB, Hramiak IM, Mahon JL (2003). "Insulin Resistance/LADA". Ann N Y Acad Sci. 1005: 374–77. Bibcode:2003NYASA1005..374B. doi:10.1196/annals.1288.062. PMID 14679095. 
  63. ^ "Latent Autoimmune Diabetes: A Little Known Type of Diabetes". Pharmacy Times. Retrieved May 30, 2014. 
  64. ^ McGarry, JD (2002). "Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes". Diabetes. 51 (1): 7–18. doi:10.2337/diabetes.51.1.7. PMID 11756317. 
  65. ^ Flores-Riveros, JR; McLenithan, JC; Ezaki, O; Lane, MD (1993). "Insulin down-regulates expression of the insulin-responsive glucose transporter (GLUT4) gene: effects on transcription and mRNA turnover". Proceedings of the National Academy of Sciences of the United States of America. 90 (2): 512–16. Bibcode:1993PNAS...90..512F. doi:10.1073/pnas.90.2.512. PMC 45693 Freely accessible. PMID 8421683. 
  66. ^ MacLean, PS; Zheng, D; Jones, JP; Olson, AL; Dohm, GL (2002). "Exercise-induced transcription of the muscle glucose transporter (GLUT 4) gene". Biochemical and Biophysical Research Communications. 292 (2): 409–14. doi:10.1006/bbrc.2002.6654. PMID 11906177. 
  67. ^ Koga M, Kasayama S (2010). "Clinical impact of glycated albumin as another glycemic control marker". Endocrine Journal. 57 (9): 751–62. doi:10.1507/endocrj.K10E-138. PMID 20724796. [permanent dead link]
  68. ^ Puddu A, Viviani GL (2011). "Advanced glycation endproducts and diabetes. Beyond vascular complications". Endocrine, Metabolic & Immune Disorders Drug Targets. 11 (2): 132–40. doi:10.2174/187153011795564115. PMID 21476962. 
  69. ^ Nagaev, I; Bokarewa, M; Tarkowski, A; Smith, U (2006). Valcarcel, Juan, ed. "Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes". PLoS ONE. 1 (1): e31. Bibcode:2006PLoSO...1...31N. doi:10.1371/journal.pone.0000031. PMC 1762367 Freely accessible. PMID 17183659. 
  70. ^ Insulin at eMedicine
  71. ^ Defronzo, RA; Tobin, JD; Andres, R (1979). "Glucose clamp technique: a method for quantifying insulin secretion and resistance". The American Journal of Physiology. 237 (3): E214–23. doi:10.1152/ajpendo.1979.237.3.e214. PMID 382871. 
  72. ^ a b c d e f Muniyappa, R; Lee, S; Chen, H; Quon, MJ (2008). "Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage". Am J Physiol Endocrinol Metab. 294 (1): E15–26. doi:10.1152/ajpendo.00645.2007. PMID 17957034. 
  73. ^ Wallace, TM; Levy, JC; Matthews, DR (2004). "Use and abuse of HOMA modeling". Diabetes Care. 27 (6): 1487–95. doi:10.2337/diacare.27.6.1487. PMID 15161807. 
  74. ^ Boden, G; Sargrad, K; Homko, C; Mozzoli, M; Stein, TP (2005). "Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes". Annals of Internal Medicine. 142 (6): 403–11. doi:10.7326/0003-4819-142-6-200503150-00006. PMID 15767618. 
  75. ^ Bramnert, M; Segerlantz, M; Laurila, E; Daugaard, JR; Manhem, P; Groop, L (2003). "Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle". The Journal of Clinical Endocrinology and Metabolism. 88 (4): 1455–63. doi:10.1210/jc.2002-020542. PMID 12679422. 
  76. ^ Giannarelli R, Aragona M, Coppelli A, Del Prato S (2003). "Reducing insulin resistance with metformin: the evidence today". Diabetes Metab. 29 (4 Pt 2): 6S28–35. doi:10.1016/s1262-3636(03)72785-2. PMID 14502098. 
  77. ^ Knowler, WC; Barrett-Connor, E; Fowler, SE; Hamman, RF; Lachin, JM; Walker, EA; Nathan, DM (2002). "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin". New England Journal of Medicine. Diabetes Prevention Program Research Group. 346 (6): 393–403. doi:10.1056/NEJMoa012512. PMC 1370926 Freely accessible. PMID 11832527. 
  78. ^ Kahn, R. (January 2012). "Reducing the impact of diabetes: Is prevention feasible today, or should we aim for better treatment?". Health Affairs. 31 (1): 76–83. doi:10.1377/hlthaff.2011.1075. PMID 22232097. 
  79. ^ Newsom, S. A.; Schenk, S.; Thomas, K. M.; Harber, M. P.; Knuth, N. D.; Goldenberg, N.; Horowitz, J. F. (2009). "Energy deficit after exercise augments lipid mobilization but does not contribute to the exercise-induced increase in insulin sensitivity". Journal of Applied Physiology. 108 (3): 554–60. doi:10.1152/japplphysiol.01106.2009. PMC 2838634 Freely accessible. PMID 20044472. 
  80. ^ Keenan, M. J.; Zhou, J.; Hegsted, M.; Pelkman, C.; Durham, H. A.; Coulon, D. B.; Martin, R. J. (Mar 2015). "Role of resistant starch in improving gut health, adiposity, and insulin resistance". Advances in Nutrition. 6 (2): 198–205. doi:10.3945/an.114.007419. PMC 4352178 Freely accessible. PMID 25770258. 
  81. ^ Higgins, JA; Miller Brand, JC; Denyer, GS (1996). "Development of insulin resistant in the rat is dependent on the rate of glucose absorption from the diet". Journal of Nutrition. 126 (3): 596–602. PMID 8598543. 
  82. ^ Byrnes, SE; Brand Miller, JC; Denyer, GS (1995). "Amylopectin starch promotes the development of insulin resistance in rats". Journal of Nutrition. 125 (6): 1430–37. PMID 7782895. 
  83. ^ Wiseman, CE; Higgins, JA; Denyer, GS; Brand Miller, JC (1996). "Amylopectin starch induces nonreversible insulin resistance in rats". Journal of Nutrition. 126 (2): 410–15. PMID 8632213. 
  84. ^ Lovejoy, Jennifer C (2002). "The influence of dietary fat on insulin resistance". Current Diabetes Reports. 2 (5): 435–40. doi:10.1007/s11892-002-0098-y. PMID 12643169. 
  85. ^ Fukuchi, S; Hamaguchi, K; Seike, M; Himeno, K; Sakata, T; Yoshimatsu, H (2004). "Role of fatty acid composition in the development of metabolic disorders in sucrose-induced obese rats". Experimental biology and medicine. 229 (6): 486–93. doi:10.1177/153537020422900606. PMID 15169967. 
  86. ^ Storlien, LH; Baur, LA; Kriketos, AD; Pan, DA; Cooney, GJ; Jenkins, AB; Calvert, GD; Campbell, LV (1996). "Dietary fats and insulin action". Diabetologia. 39 (6): 621–31. doi:10.1007/BF00418533. PMID 8781757. 
  87. ^ De la Rue, J; Lefoll, C; Corporeau, C; Lucas, D (2004). "N-3 long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity?". Reproduction, nutrition, development. 44 (3): 289–99. doi:10.1051/rnd:2004033. PMID 15460168. 
  88. ^ "Does caffeine affect blood sugar?". Mayo Clinic{{inconsistent citations}} 
  89. ^ Falta, W.; Boller, R. (1931). "Insulärer und Insulinresistenter Diabetes". Klinische Wochenschrift. 10 (10): 438–43. doi:10.1007/BF01736348. 
  90. ^ Himsworth, H (1936). "Diabetes mellitus: its differentiation into insulin-sensitive and insulin insensitive types". The Lancet. 227 (5864): 127–30. doi:10.1016/S0140-6736(01)36134-2. 
  91. ^ Nolan, C (2010). "Failure of islet β-cell compensation for insulin resistance causes type 2 diabetes: What causes non-alcoholic fatty liver disease and non-alcoholic steatohepatitis?". Journal of Gastroenterology and Hepatology. 25 (10): 1594–97. doi:10.1111/j.1440-1746.2010.06473.x. PMID 20880166. 

Further reading[edit]

External links[edit]

Classification
External resources


Retrieved from "https://en.wikipedia.org/w/index.php?title=Insulin_resistance&oldid=842530912"